Lupin Limited (LUPIN.BO)
- Previous Close
1,594.90 - Open
1,585.60 - Bid --
- Ask --
- Day's Range
1,585.60 - 1,623.90 - 52 Week Range
695.05 - 1,703.80 - Volume
21,240 - Avg. Volume
25,587 - Market Cap (intraday)
737.609B - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
41.26 - EPS (TTM)
39.23 - Earnings Date May 6, 2024
- Forward Dividend & Yield 4.00 (0.25%)
- Ex-Dividend Date Jul 14, 2023
- 1y Target Est
838.46
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilars; over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
www.lupin.com20,933
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: LUPIN.BO
Performance Overview: LUPIN.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LUPIN.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LUPIN.BO
Valuation Measures
Market Cap
726.88B
Enterprise Value
742.11B
Trailing P/E
40.71
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.82
Price/Book (mrq)
5.49
Enterprise Value/Revenue
3.89
Enterprise Value/EBITDA
21.29
Financial Highlights
Profitability and Income Statement
Profit Margin
9.19%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
194.8B
Net Income Avi to Common (ttm)
17.91B
Diluted EPS (ttm)
39.23
Balance Sheet and Cash Flow
Total Cash (mrq)
17.33B
Total Debt/Equity (mrq)
28.44%
Levered Free Cash Flow (ttm)
--
Research Analysis: LUPIN.BO
Company Insights: LUPIN.BO
LUPIN.BO does not have Company Insights